Loading...
•
Sep 30, 2021
Cerus Q3 2021 Earnings Report
Announced record third quarter financial results and raised full-year product revenue guidance.
Key Takeaways
Cerus Corporation reported a 44% increase in total revenue for Q3 2021, reaching $42.1 million, with product revenue growing by 53% to $36.1 million, driven by U.S. adoption of INTERCEPT platelets. The company raised its full-year product revenue guidance to $127-129 million.
Total revenue reached $42.1 million, a 44% increase year-over-year.
Product revenue grew 53% to $36.1 million compared to the prior year period.
The company is increasing its 2021 annual product revenue guidance range to $127 million to $129 million.
Cumulative sales for the INTERCEPT Blood System surpassed 10 million treatable doses globally.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comEurope, Middle East and Africa Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Based on strong product revenue year to date and updated demand estimates heading into the remainder of the Company’s fourth quarter, the Company now expects 2021 product revenue to be in the range of $127 million to $129 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income